Federico Díaz‐González
YOU?
Author Swipe
View article: Microbial Signatures in Psoriatic Arthritis Distinguish Disease Phenotypes and Newly Diagnosed Inflammatory Bowel Disease Independent of Fecal Calprotectin
Microbial Signatures in Psoriatic Arthritis Distinguish Disease Phenotypes and Newly Diagnosed Inflammatory Bowel Disease Independent of Fecal Calprotectin Open
Objectives There is growing evidence of microbial involvement in immune-mediated diseases, including psoriatic arthritis (PsA) and inflammatory bowel disease (IBD). It is however unclear whether different PsA phenotypes exhibit distinct mi…
View article: Design and Implementation of an ISO 9001:2015 Quality Management System in Various Organizational Sectors
Design and Implementation of an ISO 9001:2015 Quality Management System in Various Organizational Sectors Open
Introduction: The research focused on the design and implementation of a Quality Management System (QMS) under the ISO 9001:2015 standard, considering its relevance in a highly competitive organizational environment. It started from the re…
View article: Interchangeability of patient pain, fatigue and global scores in patients with spondyloarthritis - a registry-based simulation study
Interchangeability of patient pain, fatigue and global scores in patients with spondyloarthritis - a registry-based simulation study Open
View article: Prevalence of Undiagnosed Inflammatory Bowel Disease in Spondyloarthritis Patients
Prevalence of Undiagnosed Inflammatory Bowel Disease in Spondyloarthritis Patients Open
Background/Objectives: The prevalence of inflammatory bowel disease (IBD) in spondyloarthritis (SpA) patients is unknown. Our objective was to assess the prevalence of undiagnosed IBD in SpA patients, including those with axial spondylarth…
View article: ABS0401 TNF-ALPHA INHIBITORS INCREASE INCRETINS SERUM LEVELS
ABS0401 TNF-ALPHA INHIBITORS INCREASE INCRETINS SERUM LEVELS Open
View article: Disparities in the organisation of national healthcare systems for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
Disparities in the organisation of national healthcare systems for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe Open
The findings highlight substantial variability in healthcare set-ups for biologic/targeted synthetic DMARD use in psoriatic arthritis and axial spondyloarthritis across Europe and their association with socioeconomic status and drug costs.…
View article: Tocilizumab modulates the activity of the classical and alternative complement pathways in rheumatoid arthritis patients
Tocilizumab modulates the activity of the classical and alternative complement pathways in rheumatoid arthritis patients Open
Background Tocilizumab (TCZ) is a monoclonal antibody that neutralizes interleukin (IL)-6 and is indicated for diseases characterized by markedly elevated inflammatory markers, such as rheumatoid arthritis (RA). The complement system has b…
View article: Efficacy, Safety, Pharmacokinetics, and Immunogenicity of <scp>ABBV</scp>‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial
Efficacy, Safety, Pharmacokinetics, and Immunogenicity of <span>ABBV</span>‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial Open
Objective An unmet need exists for glucocorticoid‐sparing treatments for patients with polymyalgia rheumatica (PMR). The antibody‐drug conjugate ABBV‐154 comprises adalimumab conjugated to a glucocorticoid receptor modulator. We evaluated …
View article: Handgrip strength as a predictor of 1‑year mortality after hip fracture surgery in the Colombian Andes Mountains
Handgrip strength as a predictor of 1‑year mortality after hip fracture surgery in the Colombian Andes Mountains Open
View article: Early identification of golimumab-treated patients with higher likelihood of long-term retention
Early identification of golimumab-treated patients with higher likelihood of long-term retention Open
Background The early identification of patients’ profiles most likely to respond to and maintain long-term therapy with a biological drug can have clinical and cost-effectiveness implications. Objectives To evaluate the utility of an innov…
View article: P1228 The EISER Study: Identifying Microbial Factors Associated with Subclinical Gut Inflammation in Psoriatic Arthritis Patients Who Develop Inflammatory Bowel Disease
P1228 The EISER Study: Identifying Microbial Factors Associated with Subclinical Gut Inflammation in Psoriatic Arthritis Patients Who Develop Inflammatory Bowel Disease Open
Background Nearly 8% of patients with spondyloarthritis (SpA) manifest symptoms that are compatible with active inflammatory bowel disease (IBD). It is well established that microbial dysbiosis is associated with different immune-mediated …
View article: Sex Differences in the Effectiveness of First‐Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network
Sex Differences in the Effectiveness of First‐Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network Open
Objective Women with psoriatic arthritis (PsA) may have reduced tumor necrosis factor inhibitor (TNFi) effectiveness compared to men. We examined sex differences in treatment response and retention rates during 24 months of follow‐up among…
View article: Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching
Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching Open
Objective To investigate real-world effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA) and the association with (i) treatment line (second and third TNFi-series) and (ii) reason for wi…
View article: Real‐world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritis
Real‐world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritis Open
Objective The persistence of biologic (b) and targeted synthetic (ts) disease‐modifying antirheumatic drugs(DMARDs) in monotherapy versus in combination with conventional synthetic (cs) DMARDs is still a controversial topic in rheumatic di…
View article: HDL Cholesterol Efflux and the Complement System Are Linked in Systemic Lupus Erythematosus
HDL Cholesterol Efflux and the Complement System Are Linked in Systemic Lupus Erythematosus Open
Cholesterol efflux capacity (CEC), the ability of high-density lipoprotein (HDL) cholesterol to accept cholesterol from macrophages, has been linked to cardiovascular events. Systemic lupus erythematosus (SLE) is characterized by the consu…
View article: Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe Open
View article: Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases
Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases Open
Background In patients with rheumatic diseases, the use of biological (b) or targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) after discontinuation of tumor necrosis factor inhibitors (TNFi) is known to be effective. …
View article: POS0374 HOW WELL DO EULAR/ASAS-EULAR AND NATIONAL TREATMENT RECOMMENDATIONS FOR PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS ALIGN? IS IT TIME FOR AN UPDATE OF NATIONAL TREATMENT RECOMMENDATIONS?
POS0374 HOW WELL DO EULAR/ASAS-EULAR AND NATIONAL TREATMENT RECOMMENDATIONS FOR PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS ALIGN? IS IT TIME FOR AN UPDATE OF NATIONAL TREATMENT RECOMMENDATIONS? Open
View article: Full characterization of the three pathways of the complement system in patients with systemic lupus erythematosus
Full characterization of the three pathways of the complement system in patients with systemic lupus erythematosus Open
Background To date a complete characterization of the components of the complement (C) pathways (CLassical, LEctin and ALternative) in patients with systemic lupus erythematosus (SLE) has not been performed. We aimed to assess the function…
View article: Tocilizumab‐related hypertriglyceridemia is independent of key molecules regulating lipid metabolism
Tocilizumab‐related hypertriglyceridemia is independent of key molecules regulating lipid metabolism Open
Introduction Tocilizumab (TCZ) treatment is associated with dyslipidaemia, including a rise in triglycerides through a mechanism poorly understood. Three molecules play key roles in the regulation of triglyceride metabolism: apolipoprotein…
View article: Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study
Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study Open
Objective To investigate the influence of COVID-19 vaccination on disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients under targeted therapies. Patients and methods 1765 vaccinated patients COVID-19, 1178 (…
View article: Women and authorship in an international journal dedicated to cardiovascular diseases: analysis of the last decade
Women and authorship in an international journal dedicated to cardiovascular diseases: analysis of the last decade Open
Introduction and purpose Scientific production has become very important in the progression of the healthcare profession, and the studies made in this field reflect a gender gap in the authorship of such production. In the last decade, a r…
View article: Long‐term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis
Long‐term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis Open
Aim To assess the golimumab retention rate during up to 8 years of follow up, and any associated factors. Methods Retrospective analysis of the BIOBADASER (Spanish registry of biological drugs) database, assessing all adults who had ever s…
View article: Real-life persistence of targeted therapy strategy in monotherapy versus combination therapy in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
Real-life persistence of targeted therapy strategy in monotherapy versus combination therapy in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis Open
Aim: To evaluate the persistence of the initial strategy of targeted therapy, with or without conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) (combination and monotherapy strategies, respectively) in patients wit…
View article: Social Capital I: Measurement and Associations with Economic Mobility
Social Capital I: Measurement and Associations with Economic Mobility Open
In this paper-the first in a series of two papers that use data on 21 billion friendships from Facebook to study social capital-we measure and analyze three types of social capital by ZIP code in the United States: (i) connectedness betwee…
View article: POS0940 FACTORS ASSOCIATED WITH LONG-TERM RETENTION OF TREATMENT WITH GOLIMUMAB IN A LARGE COHORT OF PATIENTS WITH RHEUMATIC DISEASES, WITH UP TO 8 YEARS OF FOLLOW-UP
POS0940 FACTORS ASSOCIATED WITH LONG-TERM RETENTION OF TREATMENT WITH GOLIMUMAB IN A LARGE COHORT OF PATIENTS WITH RHEUMATIC DISEASES, WITH UP TO 8 YEARS OF FOLLOW-UP Open
View article: AB0758 Golimumab after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases: four-year retention rate in the Spanish BIOBADASER registry
AB0758 Golimumab after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases: four-year retention rate in the Spanish BIOBADASER registry Open
View article: Expert recommendations for the use of apremilast in psoriatic arthritis
Expert recommendations for the use of apremilast in psoriatic arthritis Open
The structured opinion of the experts complements the available evidence and contributes to the establishment of consensual guidelines for the use of apremilast in PsA.
View article: Recomendaciones de expertos para el uso de apremilast en artritis psoriásica
Recomendaciones de expertos para el uso de apremilast en artritis psoriásica Open
A pesar de la evidencia, existen dudas sobre el posicionamiento de apremilast en el algoritmo de tratamiento de la artritis psoriásica (APs). El objetivo del presente proyecto fue recoger la evidencia científica y la experiencia de un grup…
View article: Association of Gender, Diagnosis, and Obesity With Retention Rate of Secukinumab in Spondyloarthropathies: Results Form a Multicenter Real-World Study
Association of Gender, Diagnosis, and Obesity With Retention Rate of Secukinumab in Spondyloarthropathies: Results Form a Multicenter Real-World Study Open
Background: Secukinumab has been shown effective for psoriatic arthritis (PsA) and axial spondylarthritis (AxSpA) in randomized trials. The aim of this study was to analyze baseline patient and disease characteristics associated with a bet…